AR100153A1 - Medicamento - Google Patents
MedicamentoInfo
- Publication number
- AR100153A1 AR100153A1 ARP150101205A ARP150101205A AR100153A1 AR 100153 A1 AR100153 A1 AR 100153A1 AR P150101205 A ARP150101205 A AR P150101205A AR P150101205 A ARP150101205 A AR P150101205A AR 100153 A1 AR100153 A1 AR 100153A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutically acceptable
- brexpiprazole
- nalmefene
- acceptable salt
- acceptable salts
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 abstract 12
- WJBLNOPPDWQMCH-MBPVOVBZSA-N Nalmefene Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=C)O)CC1)O)CC1CC1 WJBLNOPPDWQMCH-MBPVOVBZSA-N 0.000 abstract 6
- ZKIAIYBUSXZPLP-UHFFFAOYSA-N brexpiprazole Chemical compound C1=C2NC(=O)C=CC2=CC=C1OCCCCN(CC1)CCN1C1=CC=CC2=C1C=CS2 ZKIAIYBUSXZPLP-UHFFFAOYSA-N 0.000 abstract 6
- 229960001210 brexpiprazole Drugs 0.000 abstract 6
- 229960005297 nalmefene Drugs 0.000 abstract 6
- 239000003814 drug Substances 0.000 abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 abstract 4
- 208000011117 substance-related disease Diseases 0.000 abstract 2
- 208000028505 alcohol-related disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Addiction (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Reivindicación 1: Un medicamento caracterizado porque comprende (I) brexpiprazol o una de sus sales farmacéuticamente aceptables y (II) nalmefeno o una de sus sales farmacéuticamente aceptables en combinación, en donde brexpiprazol o una de sus sales farmacéuticamente aceptables y nalmefeno o una de sus sales farmacéuticamente aceptables están contenidos en una mono preparación o una composición farmacéutica que contiene brexpiprazol o una de sus sales farmacéuticamente aceptables y una composición farmacéutica que contiene nalmefeno o una de sus sales farmacéuticamente aceptables se formulan para usar en combinación. Reivindicación 4: El medicamento de acuerdo con cualquiera de las reivindicaciones 1 a 3, caracterizado porque es para usar en la prevención o el tratamiento de un trastorno relacionado con sustancia. Reivindicación 5: El medicamento de acuerdo con la reivindicación 4, caracterizado porque el trastorno relacionado con sustancia es un trastorno relacionado con el alcohol. Reivindicación 14: Una composición farmacéutica caracterizada porque comprende (I) brexpiprazol o una de sus sales farmacéuticamente aceptables, (II) nalmefeno o una de sus sales farmacéuticamente aceptables y (III) un portador farmacológicamente aceptable. Reivindicación 15: Un método para producir una composición farmacéutica, caracterizado porque comprende mezclar (I) brexpiprazol o una de sus sales farmacéuticamente aceptables y (II) nalmefeno o una de sus sales farmacéuticamente aceptables con un portador farmacológicamente aceptable. Reivindicación 16: Un kit caracterizado porque comprende (I) un medicamento que contiene brexpiprazol o una de sus sales farmacéuticamente aceptables y (II) un medicamento que contiene nalmefeno o una de sus sales farmacéuticamente aceptables.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014088148 | 2014-04-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR100153A1 true AR100153A1 (es) | 2016-09-14 |
Family
ID=53191808
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150101205A AR100153A1 (es) | 2014-04-22 | 2015-04-22 | Medicamento |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US20170042887A1 (es) |
| EP (1) | EP3134090B1 (es) |
| JP (1) | JP6797691B2 (es) |
| KR (1) | KR20160138301A (es) |
| CN (1) | CN106456634A (es) |
| AR (1) | AR100153A1 (es) |
| AU (1) | AU2015250611A1 (es) |
| BR (1) | BR112016024510A2 (es) |
| CA (1) | CA2946698A1 (es) |
| CL (1) | CL2016002653A1 (es) |
| ES (1) | ES2742888T3 (es) |
| IL (1) | IL248381A0 (es) |
| MX (1) | MX2016013889A (es) |
| PH (1) | PH12016502107A1 (es) |
| RU (1) | RU2016145411A (es) |
| SG (2) | SG10201809280PA (es) |
| TW (1) | TW201625252A (es) |
| WO (1) | WO2015163486A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023173950A (ja) * | 2022-05-27 | 2023-12-07 | 同仁医薬化工株式会社 | 経口液剤 |
| US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3814768A (en) | 1971-11-26 | 1974-06-04 | Lewenstein E | 6-methylene-6-desoxy dihydro morphine and codeine derivatives and pharmaceutically acceptable salts |
| US4535157A (en) | 1983-11-01 | 1985-08-13 | Key Pharmaceuticals, Inc. | Process for making 6-desoxy-6-methylenenaloxone and 6-desoxy-6-methylenenaltrexone |
| US4751307A (en) | 1985-01-17 | 1988-06-14 | Mallinckrodt, Inc. | Wittig-reaction processes |
| US5086058A (en) | 1990-06-04 | 1992-02-04 | Alko Ltd. | Method for treating alcoholism with nalmefene |
| US20060235038A1 (en) * | 1996-05-06 | 2006-10-19 | Simon David L | Novel therapeutic uses for nalmefene |
| EP1011671A1 (en) * | 1997-05-20 | 2000-06-28 | Yale University | Substance dependence treatment using opiate antagonists and serotonin compounds |
| AR031682A1 (es) | 1999-11-19 | 2003-10-01 | Reckitt Benckiser Helthcare Uk | Composiciones farmaceuticas |
| US7923454B2 (en) * | 2002-05-17 | 2011-04-12 | Jenken Biosciences, Inc. | Opioid and opioid-like compounds and uses thereof |
| UA83504C2 (en) * | 2003-09-04 | 2008-07-25 | Селджин Корпорейшн | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| US20050245541A1 (en) * | 2004-03-19 | 2005-11-03 | Elliot Ehrich | Methods for treating alcoholism |
| TWI320783B (en) | 2005-04-14 | 2010-02-21 | Otsuka Pharma Co Ltd | Heterocyclic compound |
| AR058239A1 (es) * | 2005-11-28 | 2008-01-23 | Orexigen Therapeutics Inc | Metodos para tratar trastornos de ansiedad |
| JP4540700B2 (ja) | 2006-10-13 | 2010-09-08 | 大塚製薬株式会社 | 医薬 |
| US20100168119A1 (en) * | 2008-11-05 | 2010-07-01 | Pharmorx, Inc. | Compositions and methods for minimizing or reducing agonist-induced desensitization |
| UA102128C2 (en) | 2008-12-05 | 2013-06-10 | Х. Луннбек А/С | Nalmefene hydrochloride dihydrate |
| SI2435439T1 (sl) | 2009-05-25 | 2016-06-30 | H. Lundbeck A/S | Priprava nalmefen hidroklorida iz naltreksona |
| ES2620660T3 (es) | 2010-11-05 | 2017-06-29 | H. Lundbeck A/S | Método para la fabricación de naltrexona |
| TWI636784B (zh) | 2011-04-05 | 2018-10-01 | 大塚製藥股份有限公司 | 含7-〔4-(4-苯並〔b〕噻吩-4-基-哌-1-基)丁氧基〕-1H-喹啉-2-酮之醫藥組成物與套組，以及彼之用途 |
| TWI562991B (en) | 2012-04-23 | 2016-12-21 | Otsuka Pharma Co Ltd | Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same |
| US20140005216A1 (en) | 2012-06-27 | 2014-01-02 | H. Lundbeck A/S | Nalmefene for reduction of alcohol consumption in specific target populations |
| JOP20210047A1 (ar) * | 2012-10-25 | 2017-06-16 | Otsuka Pharma Co Ltd | عامل وقائي و/أو علاجي للأعراض السلوكية والنفسية المصحوبة بمرض تنكسي عصبي أو الأعراض الإندفاعية المصحوبة بمرض ذهني، يحتوي على بريكسبيرازول أو ملحه |
| JP2014088148A (ja) | 2012-10-31 | 2014-05-15 | Daihatsu Motor Co Ltd | 車体構造 |
| US20150342946A1 (en) * | 2013-01-30 | 2015-12-03 | Pharmorx Therapeutics, Inc. | Treatments For Depression And Other Diseases With A Low Dose Agent |
-
2015
- 2015-04-22 BR BR112016024510A patent/BR112016024510A2/pt not_active IP Right Cessation
- 2015-04-22 SG SG10201809280PA patent/SG10201809280PA/en unknown
- 2015-04-22 RU RU2016145411A patent/RU2016145411A/ru not_active Application Discontinuation
- 2015-04-22 US US15/305,782 patent/US20170042887A1/en not_active Abandoned
- 2015-04-22 KR KR1020167031443A patent/KR20160138301A/ko not_active Withdrawn
- 2015-04-22 CN CN201580021154.1A patent/CN106456634A/zh active Pending
- 2015-04-22 WO PCT/JP2015/062913 patent/WO2015163486A1/en not_active Ceased
- 2015-04-22 TW TW104112862A patent/TW201625252A/zh unknown
- 2015-04-22 ES ES15723775T patent/ES2742888T3/es active Active
- 2015-04-22 JP JP2016564114A patent/JP6797691B2/ja active Active
- 2015-04-22 EP EP15723775.1A patent/EP3134090B1/en active Active
- 2015-04-22 MX MX2016013889A patent/MX2016013889A/es unknown
- 2015-04-22 AR ARP150101205A patent/AR100153A1/es unknown
- 2015-04-22 AU AU2015250611A patent/AU2015250611A1/en not_active Abandoned
- 2015-04-22 CA CA2946698A patent/CA2946698A1/en not_active Abandoned
- 2015-04-22 SG SG11201608766TA patent/SG11201608766TA/en unknown
-
2016
- 2016-10-18 IL IL248381A patent/IL248381A0/en unknown
- 2016-10-19 CL CL2016002653A patent/CL2016002653A1/es unknown
- 2016-10-21 PH PH12016502107A patent/PH12016502107A1/en unknown
-
2019
- 2019-01-17 US US16/250,548 patent/US20190151309A1/en not_active Abandoned
-
2020
- 2020-08-13 US US16/992,551 patent/US11642341B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3134090B1 (en) | 2019-06-05 |
| CN106456634A (zh) | 2017-02-22 |
| US20170042887A1 (en) | 2017-02-16 |
| RU2016145411A (ru) | 2018-05-23 |
| MX2016013889A (es) | 2017-03-09 |
| SG10201809280PA (en) | 2018-11-29 |
| JP2017513895A (ja) | 2017-06-01 |
| PH12016502107A1 (en) | 2017-01-09 |
| AU2015250611A1 (en) | 2016-11-24 |
| US11642341B2 (en) | 2023-05-09 |
| US20190151309A1 (en) | 2019-05-23 |
| SG11201608766TA (en) | 2016-11-29 |
| BR112016024510A2 (pt) | 2017-08-15 |
| TW201625252A (zh) | 2016-07-16 |
| CA2946698A1 (en) | 2015-10-29 |
| CL2016002653A1 (es) | 2017-04-21 |
| KR20160138301A (ko) | 2016-12-02 |
| JP6797691B2 (ja) | 2020-12-09 |
| IL248381A0 (en) | 2016-11-30 |
| ES2742888T3 (es) | 2020-02-17 |
| RU2016145411A3 (es) | 2018-10-03 |
| EP3134090A1 (en) | 2017-03-01 |
| WO2015163486A1 (en) | 2015-10-29 |
| US20200368227A1 (en) | 2020-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2018000318A1 (es) | Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925) | |
| MX376329B (es) | Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso. | |
| CO2017004525A2 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
| CL2016002517A1 (es) | Uso de ácido r-2-4-2-etoxi-3-4-trifluormetilfenoxipropil-tio-2-metilfenoxi acético o una sal del mismo en la fabricación de un medicamento para tratar una condición que es una enfermedad de hígado graso no alcohólico o esteatohepatitis no alcohólica. | |
| CL2017000469A1 (es) | Derivados de tetrahidronaftaleno que inhiben la proteina mcl-1 | |
| MX383866B (es) | Inhibidores de ezh2 para tratar linfomas. | |
| CL2015003690A1 (es) | Uso de pridopidina o una sal de la misma para preparar un medicamento útil en el tratamiento de la enfermedad de huntington. | |
| CO2018004857A2 (es) | Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer | |
| MX2016008131A (es) | Compuestos heterociclos biciclicos y sus usos en terapia. | |
| MX2016015434A (es) | Combinaciones farmaceuticas para tratar cancer. | |
| GT201500053A (es) | Composicion farmaceutica recubierta que contiene regorafenib | |
| CL2016000241A1 (es) | Formulación de inhibidores de la syk. | |
| AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
| DOP2016000254A (es) | Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso. | |
| MX2016015437A (es) | Combinacion que comprende un glucocorticoide y edo-s101. | |
| AR101414A1 (es) | Derivados de pirrolidinona como inhibidores de metap-2 | |
| AR097619A1 (es) | Uso de inhibidores de acetil-coa carboxilasa para tratar acné vulgaris | |
| MX2017003780A (es) | Composicion farmaceutica para tratar colitis ulcerativa. | |
| NI201800071A (es) | Compuestos de isoindol | |
| DOP2016000297A (es) | Composiciones farmacéuticas útiles para tratar enfermedades infecciosas | |
| UY37729A (es) | NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7 | |
| CL2016002318A1 (es) | Composición farmacéutica en forma de solución que comprende un portador líquido que comprende agua y entre 20% y 95% de uno o mas alcoholes y citrato de sildenafil disuelto en dicho portador líquido a una concentración de entre 7 y 125 mg/ml; métodos para obtenerla; forma de dosificación oral; forma de dosificación bucal; kits. | |
| CL2016000397A1 (es) | Tratamiento contra el cáncer | |
| CL2018002848A1 (es) | Formulaciones liquidas de fosfoplatino | |
| AR100153A1 (es) | Medicamento |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |